CompletedPhase 1

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

United States150 participantsStarted 2018-07-10

Plain-language summary

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb20717 in subjects with selected advanced solid tumors.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Melanoma;
✓. Breast carcinoma that is estrogen receptor, progesterone receptor, and Her2 negative (triple-negative breast cancer; TNBC);
✓. Hepatocellular carcinoma;
✓. Urothelial carcinoma;
✓. Squamous cell carcinoma of the head and neck;
✓. Renal cell carcinoma (clear cell predominant type);
✓. Microsatellite instability-high or mismatch repair deficient colorectal carcinoma or endometrial carcinoma;
✓. Non-small cell lung carcinoma;

What they're measuring

Determine the safety and tolerability profile of XmAb20717

Timeframe: 56 Days

Trial details

NCT IDNCT03517488

SponsorXencor, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2022-06-01

View on ClinicalTrials.gov More Melanoma trials